Simultaneous determination of acetylsalicylic acid and caffeine in pharmaceutical formulation by first derivative synchronous fluorimetric method.
A sensitive, rapid, and specific assay has been developed for the simultaneous determination of acetylsalicylic acid and caffeine in commercial tablets based on their natural fluorescence. The mixture of these drugs was resolved by first derivative synchronous fluorimetric technique using two scans. At Deltalambda=106 nm, using first derivative synchronous scanning, only acetylsalicylic acid yields a detectable signal at 316 nm (peak to zero method) which is unaffected by caffeine. At Deltalambda=30 nm, the signal of caffeine at 288 nm (peak to zero method) is not affected by acetylsalicylic acid. The range of application is between 0.021 and 41.62 microg ml(-1) (correlation coefficient, R=0.9995) for acetylsalicylic acid and between 0.4486 and 44.86 microg ml(-1) (correlation coefficient, R=0.99786) for caffeine. The recovery range of 98.40-102% for acetylsalicylic acid and 90-100.5% for caffeine from their synthetic mixture was reported. Overall recovery of both compounds about 97-99% for acetylsalicylic acid and 97-98% for caffeine was obtained from real sample analysis. The detection limits are 0.0013 microg ml(-1) and 0.0306 microg ml(-1) for acetylsalicylic acid and caffeine, respectively. The relative standard deviation (n=10) for 20 microg ml(-1) of acetylsalicylic acid is 2.75% and for 2.2 microg ml(-1)of caffeine is 1.7%.
Karim
Mohammad Mainul
MM
Department of Chemistry, Kyungpook National University, Taegu 702-701, Republic of Korea.
Jeon
Chi Wan
CW
Lee
Hyun Sook
HS
Alam
Seikh Mafiz
SM
Lee
Sang Hak
SH
Choi
Jong Ha
JH
Jin
Seung Oh
SO
Das
Ajoy Kumar
AK
D001241:Aspirin / Q000008:administration & dosage / Q000032:analysis*; D002110:Caffeine / Q000008:administration & dosage / Q000032:analysis*; D004338:Drug Combinations; D006863:Hydrogen-Ion Concentration; D013050:Spectrometry, Fluorescence / Q000379:methods* / Q000706:statistics & numerical data; D013501:Surface-Active Agents; D013607:Tablets
D004338:Drug Combinations; D013501:Surface-Active Agents; D013607:Tablets; D002110:Caffeine; D001241:Aspirin